Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Burrill &a; Company Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Burrill &a; Company is a venture capital and private equity firm that invests in life sciences, biotechnology, and healthcare companies.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2003 | Emerald BioAgriculture Corporation | Venture Round | 0 |
| 3/2009 | Intranasal Therapeutics | Series B | 0 |
| 9/2008 | Osprey Pharmaceuticals USA | Series A | 11M |
| 3/2008 | NanoVasc | Series A | 4.7M |
| 5/2006 | Cardiokine | Series B | 50M |
| 8/2001 | Morphotek | Series B | 0 |
| 1/2004 | Phytomedics | Series A | 7.5M |
| 6/2007 | Phytomedics | Series B | 9M |
| 8/2012 | Waterstone Pharmaceuticals | Series B | 3.4M |
| 10/2013 | BetterDoctor | Seed Round | 0 |
| 11/2012 | MabVax Therapeutics | Series B | 5.3M |
| 5/2001 | BioMimetic Therapeutics | Series A | 6.5M |
| 9/2012 | Catalyst Biosciences | Post-IPO Equity | 13.4M |
| 1/2006 | Adlyfe | Series A | 3.3M |
| 2/2012 | ADMA Biologics | Venture Round | 0 |
| 5/2005 | BioMimetic Therapeutics | Series C | 11.8M |
| 8/2011 | AliveCor | Series A | 0 |
| 3/2004 | Spectral Genomics | Series B | 9.3M |
| 8/2008 | BioImagene | Series D | 26M |
| 4/2007 | Natural Dentist | Series B | 13.2M |
| 11/2006 | Natural Dentist | Series B | - |
| 10/2005 | Alinea Pharmaceuticals | Series A | 45M |
| 2/2013 | Strand Life Sciences | Series B | - |
| 5/2007 | Arete Therapeutics | Series A | 35M |
| 11/2004 | Neosil | Series A | 32M |
| 4/2012 | WhiteGlove Health | Series E | 0 |
| 8/2011 | Ceptaris Therapeutics | Series D | 14.4M |
| 6/2012 | Ceptaris Therapeutics | Series D | 10M |
| 12/2000 | Circe Biomedical | Private Equity Round | 28M |
| 1/2010 | Endocyte | Series C | 26M |
| 4/2006 | Chromatin | Venture Round | 0 |
| 6/2009 | Virdia | Series A | 5.5M |
| 4/2004 | Efficas | Series A | 4.7M |
| 4/2009 | Aerovance | Venture Round | 38M |
| 1/2007 | diaDexus | Post-IPO Equity | 0 |
| 5/2013 | NewBridge Pharmaceuticals | Series C | 0 |
| 3/2012 | Virdia | Series A | 20M |
| 9/2010 | NewBridge Pharmaceuticals | Series B | 12M |
| 8/2009 | SchoolCare | Series G | 14.4M |
| 8/2009 | Gevo | Venture Round | 0 |
| 5/2010 | Gevo | Series D | 0 |
| 10/2001 | GeneFormatics | Venture Round | 0 |
| 10/2012 | Cobalt Technologies | Venture Round | 5M |
| 4/2012 | Cobalt Technologies | Venture Round | 2.9M |
| 6/2001 | Corus Pharma | Series A | 18.5M |
| 9/2002 | Alexza Pharmaceuticals | Series A | 0 |
| 9/2007 | Chlorogen | Venture Round | 0 |
| 8/2005 | Chlorogen | Series B | 0 |
| 3/2007 | Endocyte | Series C | 15M |
| 2/2000 | DoubleTwist | Series D | 37M |
| 12/2005 | SchoolCare | Series E | 26.5M |
| 9/2004 | Sciona | Series B | 4.1M |
| 3/2007 | Aerovance | Series C | 60M |
| 7/2007 | Light Sciences Oncology | Series B | 30M |
| 5/2008 | Gevo | Series C | 17M |
| 11/2006 | Endocyte | Venture Round | 30M |
| 8/2008 | Wellpartner | Series D | 0 |
| 4/2014 | Nora Therapeutics | Series B | 18M |
| 12/2006 | Dreamerz Foods | Series A | 4M |
| 6/2007 | Dreamerz Foods | Series B | 10M |
| 11/2006 | Neurotech | Series B | 0 |
| 4/2012 | WaveTec Vision | Venture Round | 0 |
| 4/2004 | Cardiokine | Series A | 37M |
| 3/2007 | ProteoGenix | Series B | 20M |
| 3/2014 | Neos Therapeutics | Series C | 15.5M |
| 11/2004 | BioMimetic Therapeutics | Series C | 25.7M |
| 6/2007 | Logical Therapeutics | Series B | 30M |
| 2/2006 | Catalyst Biosciences | Series B | 30M |
| 1/2008 | PrimeraDx (Primera Biosystems) | Series B | 21M |
| 8/2004 | Aerovance | Series B | 32M |
| 4/2006 | Sciona | Series C | 9.9M |
| 2/2013 | Odyssey Thera | Venture Round | 0 |
| 2/2005 | Brand New Brands | Series A | 15M |
| 6/2004 | Nucleonics | Series B | 49.2M |
| 1/2001 | Bruker | Post-IPO Equity | 22.5M |
| 10/2006 | Morphotek | Series D | 0 |
| 11/2009 | FerroKin Biosciences | Venture Round | 15M |
| 6/2010 | FerroKin Biosciences | Series B | 12M |
| 12/2008 | Catalyst Biosciences | Post-IPO Equity | 40M |
| 10/2009 | PrimeraDx (Primera Biosystems) | Series C | 20M |
| 4/2013 | Catalyst Biosciences | Post-IPO Equity | 5.1M |
| 12/2004 | SchoolCare | Series D | 20M |
| 2/2004 | Morphotek | Series C | 26M |
| 2/2015 | Neos Therapeutics | Venture Round | 20.6M |
| 6/2012 | AliveCor | Series B | 0 |
| 12/2002 | Catalyst Bioscience | Venture Round | 46M |
| 1/2005 | Alexza Pharmaceuticals | Series D | 0 |
| 5/2003 | BioMimetic Therapeutics | Series B | 5M |
| 4/2004 | Corus Pharma | Series C | 0 |
| 7/2003 | Immunicon | Series F | 24.8M |
| 8/2006 | Intranasal Therapeutics | Series A | 0 |
| 2/2015 | Neos Therapeutics | Venture Round | 0 |
| 4/2014 | Nora Therapeutics | Series B | 0 |
| 3/2014 | Neos Therapeutics | Series C | 0 |
| 10/2013 | BetterDoctor | Seed Round | 0 |
| 5/2013 | NewBridge Pharmaceuticals | Series C | 0 |
| 4/2013 | Catalyst Biosciences | Post-IPO Equity | 0 |
| 2/2013 | Strand Life Sciences | Series B | - |
| 2/2013 | Odyssey Thera | Venture Round | 0 |
| 11/2012 | MabVax Therapeutics | Series B | 0 |
| 10/2012 | Cobalt Technologies | Venture Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
